Regeneron Pharmaceuticals has won FDA accelerated approval of its Lynozyfic treatment for certain patients with the blood ...

Regeneron Pharmaceuticals said on Wednesday the U.S. Food and Drug Administration has approved its drug for a type of blood ...

Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN) is one of the 10 Best Value Stocks to Buy According to Billionaires. Regeneron ...

Regeneron Pharmaceuticals, Inc. (REGN) on Wednesday announced that the U.S. Food and Drug Administration has granted ...

Another BCMA-targeted agent has arrived for the treatment of multiple myeloma. | After a delay, Regeneron’s BCMA-directed ...

Regeneron said on Monday its experimental drug helped patients preserve up to 51% of lean mass and lose more fat when used in combination with Novo Nordisk's popular obesity drug Wegovy in a mid-stage ...

Allspring Global Investments Holdings LLC lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report ...

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) was downgraded by stock analysts at Argus from a “buy” rating to a ...

Whales with a lot of money to spend have taken a noticeably bullish stance on Regeneron Pharmaceuticals. If we consider the specifics of each trade, it is accurate to state that 50% of the investors ...

Regeneron Pharmaceuticals, Inc. faces challenges with Eylea sales but sees growth from Dupixent and obesity drugs. Click for ...

Regeneron is hoping a new program will widen patient access to its eye drug without also benefiting the company's rivals — a ...

Lynozyflic is one of two bispecific antibodies Regeneron hopes will lift its oncology business. Meanwhile, IGM is the latest struggling biotech to agree to a buyout deal from Concentra.